#clinical - Techseriesinsight

April 30, 2025
PRNewswire
Healthcare

Gedeon Richter: Medical Treatment of Endometriosis with a progressive approach

Modern medical treatment options for endometriosis were among the main topics at the SEUD Congress (Society of Endometriosis and Uterine Disorders) held in Prague between 24-26 April, where a highly successful symposium took...

April 29, 2025
PRNewswire
Biotechnology

Announcing Veeva AI

Veeva Systems (NYSE: VEEV) today announced Veeva AI, a major new initiative that adds AI to the Veeva Vault Platform and Veeva applications to help life sciences companies automate tasks and improve...

April 25, 2025
PRNewswire
Healthcare

LAUNCH OF ORMCO™ ETCHFREE BONDING ELIMINATES ACID ETCHING

Ormco™ Corporation, a global leader in orthodontic solutions for over 60 years, is thrilled to announce the modernization of the commonplace adhesive and bonding process with the introduction of...

April 24, 2025
PRNewswire
Biotechnology

Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep’s Tumor-Fighting Mechanism of Action

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, will present new data from Cohort 1 of the GOBLET study at the 2025 American Society...

April 16, 2025
PRNewswire
Biotechnology

An Open Letter to Shareholders of TransCode Therapeutics, Inc. Asking Stockholders to Vote FOR the Proposal to Authorize a Reverse Stock Split if Necessary

TransCode Therapeutics, Inc. today released an open letter to stockholders regarding the upcoming special meeting to be held April 21. Stockholders are asked to approve a Reverse Split should...

April 15, 2025
PRNewswire
Biotechnology

ThirtyFiveBio Closes Bridge Round of Financing Highlighted by Strategic New Investment from AbbVie Ventures

ThirtyFiveBio Limited, a biotechnology company developing first-in-class small molecule inhibitors of G protein-coupled receptor 35 (GPR35) for the treatment of gastrointestinal (GI) disease, today announced the closing of a...

April 15, 2025
PRNewswire
Biotechnology

MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced positive results from the 4-week multiple ascending dose (MAD) Part 2 of its Phase 1 clinical trial...

April 14, 2025
PRNewswire
Biotechnology

Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today...

April 10, 2025
PRNewswire
Biotechnology

South Rampart Pharma Strengthens Board with Appointment of Ochsner Health CEO Pete November

South Rampart Pharma, Inc. (“South Rampart” or the “Company”), a clinical-stage biotechnology company advancing best-in-class, non-opioid pain therapeutics, today announced the appointment of Pete November, CEO of Ochsner Health, to...

April 3, 2025
PRNewswire
Healthcare

Lumen Bioscience’s LMN-201 Achieves 100% Initial C. difficile Clinical Cure in Preliminary Cohort of RePreve Trial

In a landmark achievement for its pioneering spirulina-based drug development platform, Lumen announced today top-line results from the sentinel cohort of its RePreve Clinical Trial evaluating LMN-201 for Clostridioides difficile infection (CDI). LMN-201...